Viewing Study NCT06578949



Ignite Creation Date: 2024-10-26 @ 3:39 PM
Last Modification Date: 2024-10-26 @ 3:39 PM
Study NCT ID: NCT06578949
Status: RECRUITING
Last Update Posted: None
First Post: 2024-08-28

Brief Title: Efficacy Safety Pharmacokinetics Pharmacodynamics and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria PNH
Sponsor: None
Organization: None

Study Overview

Official Title: A Phase 3 Single-arm Open-label Multicenter Study to Assess the Efficacy Safety Pharmacokinetics Pharmacodynamics and Immunogenicity of Ravulizumab in Complement Inhibitor Treatment Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria PNH in China
Status: RECRUITING
Status Verified Date: 2024-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The primary objective of this study is to evaluate the efficacy of ravulizumab in adult participants with PNH
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None